CNS penetrant potent inhibitor of SARS-CoV-2 Mpro that bind at the Mpro catalytic site
MR6-31-2, a CNS penetrant ebselen analog, is a potent inhibitor of SARS-CoV-2 Mpro that bind at the Mpro catalytic site. MR6-31-2 donates a selenium atom, forming a covalent bond and blocking the histidine-Cys catalytic dyad. It exhibits good neuroprotective effects and low cytotoxicity in cell-based and mouse models of motor neuron disease. MR6-31-2 covalently binds to A4V superoxide dismutase-1 (SOD1) and promotes its thermal stability.
Mutations to the gene encoding superoxide dismutase-1 (SOD1) were the first genetic elements discovered that cause motor neuron disease (MND). These mutations result in compromised SOD1 dimer stability, with one of the severest and most common mutations Ala4Val (A4V) displaying
The SARS-CoV-2 pandemic has triggered global efforts to develop therapeutics. The main protease of SARS-CoV-2 (Mpro), critical for viral replication, is a key target for therapeutic development. An organoselenium drug called ebselen has been demonstrated to have potent Mpro inhibition and
The SARS-CoV-2 pandemic has triggered global efforts to develop therapeutics. The main protease of SARS-CoV-2 (Mpro), critical for viral replication, is a key target for therapeutic development. An organoselenium drug called ebselen has been demonstrated to have potent Mpro inhibition and
Mutations to the gene encoding superoxide dismutase-1 (SOD1) were the first genetic elements discovered that cause motor neuron disease (MND). These mutations result in compromised SOD1 dimer stability, with one of the severest and most common mutations Ala4Val (A4V) displaying
Questions
Reviews
★★★★★ No rating value
Active Filters
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.